Table 1.
Basic information of the 126 NSCLC patients and correlation between four tumor types according to PD-L1 expression and TIL status and clinical parameters
| Characteristics | Total N=126 N (%) |
Type I N=37, 29.4% n (%) |
Type II N=30, 23.8% n (%) |
Type III N=6, 4.8% n (%) |
Type IV N=53, 42% n (%) |
P (Type I vs. Type II vs. Type III vs. Type IV) | |
|---|---|---|---|---|---|---|---|
| Gender | Male | 91 (72.2) | 36 (97.3) | 16 (53.3) | 5 (83.3) | 34 (64.2) | <0.001* |
| Female | 35 (27.8) | 1 (2.7) | 14 (46.7) | 1 (16.7) | 19 (35.8) | ||
| Smoking | Never smokers | 52 (41.3) | 4 (10.8) | 19 (63.3) | 2 (33.3) | 27 (50.9) | <0.001* |
| Ever Smokers | 74 (58.7) | 33 (89.2) | 11 (36.7) | 4 (66.7) | 26 (49.1) | ||
| Age | <60 years | 63 (50.0) | 9 (24.3) | 18 (60.0) | 4 (66.7) | 32 (60.4) | 0.002* |
| ≥60 years | 63 (50.0) | 28 (75.7) | 12 (40.0) | 2 (33.3) | 21 (39.6) | ||
| Histological types | AD | 63 (50.0) | 7 (18.9) | 22 (73.3) | 3 (50) | 31 (58.5) | <0.001* |
| Non-AD | 63 (50.0) | 30 (81.1) | 8 (26.7) | 3 (50) | 22 (41.5) | ||
| Tumor grade | Low differentiation | 33 (26.2) | 13 (35.1) | 6 (20) | 1 (16.7) | 13 (24.5) | 0.522 |
| Other grades | 93 (73.8) | 24 (64.9) | 24 (80) | 5 (83.3) | 40 (75.5) | ||
| Clinical stage | I-II | 56 (44.4) | 17 (45.9) | 16 (53.3) | 3 (50) | 20 (37.7) | 0.551 |
| IIIA | 70 (55.6) | 20 (54.1) | 14 (46.7) | 3 (50) | 33 (62.3) | ||
| EGFR mutation | +ve | 24 (19.0) | 1 (2.7) | 8 (26.7) | 1 (16.7) | 14 (26.4) | 0.008* |
| -ve | 102 (81.0) | 36 (97.3) | 22 (73.3) | 5 (83.3) | 39 (73.6) | ||
| KRAS mutation | +ve | 6 (4.8) | 5 (13.5) | 1 (3.3) | 0 | 0 | 0.003* |
| -ve | 120 (95.2) | 32 (86.5) | 29 (96.7) | 6 (100) | 53 (100) | ||
Abbreviations: AD: adenocarcinoma; EGFR: epidermal growth factor receptor; KRAS: Kirsten rat sarcoma viral oncogene; NSCLC: non-small cell lung cancer; TIL: tumor infiltrating lymphocytes.
+ve and -ve represent positive and negative results. *P≤0.05.